NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NINDS E-143-2002-1-FI-60 Method For the Treatment of Multiple Sclerosis FI EP 10182563.6 Abandoned
NINDS E-143-2002-1-DK-57 Method For the Treatment of Multiple Sclerosis DK EP 10182563.6 Abandoned
NINDS E-143-2002-1-DE-56 Method For the Treatment of Multiple Sclerosis DE EP 10182563.6 Abandoned
NINDS E-143-2002-1-EE-58 Method For the Treatment of Multiple Sclerosis EE EP 10182563.6 Abandoned
NINDS E-143-2002-1-FR-61 Method For the Treatment of Multiple Sclerosis FR EP 10182563.6 Abandoned
NINDS E-143-2002-1-EP-03 Method For the Treatment of Multiple Sclerosis EP National Stage 03762181.0 Abandoned
NINDS E-143-2002-1-CA-06 Method For the Treatment of Multiple Sclerosis CA National Stage 2490186 Abandoned
NINDS E-143-2002-1-AU-05 Method For the Treatment of Multiple Sclerosis AU National Stage 2003247813 Abandoned
NHLBI E-160-2002-0-AU-06 Trypotophan as a Functional Replacement for ADP-Ribose-Arginine in Recombinant Proteins AU National Stage 2003247826 Abandoned
NINDS E-143-2002-1-US-02 Method For the Treatment of Multiple Sclerosis US ORD 10/607,598 7258859 Abandoned PDF
NHLBI E-160-2002-0-PCT-02 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins PCT PCT PCT/US2003/020498 Expired
NINDS E-143-2002-1-PCT-01 Method For the Treatment of Multiple Sclerosis PCT PCT COMB PCT/US2003/020428 Expired
NHLBI E-160-2002-0-EP-04 Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins EP National Stage 03762212.3 Abandoned
NIDDK E-264-2003-0-US-01 Pyridinium Compounds To Treat Cystic Fibrosis And Other IL-8 Dependent Disorders US 60/482,764 Abandoned
NINDS E-143-2002-1-CA-45 Method For the Treatment of Multiple Sclerosis CA DIV 2844639 Abandoned
NHLBI E-160-2002-0-CA-05 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins CA National Stage 2490290 Abandoned
NINDS E-143-2002-1-IL-46 Method For the Treatment of Multiple Sclerosis IL DIV 241920 Abandoned
NCI E-013-2002-0-CA-06 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors CA National Stage 2490659 Abandoned
NCI E-013-2002-0-DE-10 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors DE EP 03762161.2 Abandoned
NCI E-013-2002-0-FR-11 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors FR EP 03762161.2 Abandoned
NCI E-013-2002-0-GB-12 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors GB EP 03762161.2 Abandoned
NCI E-013-2002-0-EP-04 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors EP National Stage 03762161.2 Abandoned
NCI E-013-2002-0-AU-05 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors AU National Stage 2003248744 Abandoned
NCI E-040-1996-0-US-08 METHODS AND COMPOSITIONS FOR TRANSFORMING DENDRITIC CELLS AND ACTIVATING T CELLS US DIV 10/607,327 7378277 Expired PDF
NHLBI E-211-2002-0-PCT-02 Il-21 Critically Regulates Immunoglobulin Production PCT PCT PCT/US03/20370 Abandoned
NCI E-262-2000-1-PCT-02 SH2 Domain Binding Inhibitors PCT PCT PCT/US03/19987 Expired
NCI E-013-2002-0-PCT-02 Humanized Anti-Tag 72 CC49 for Diagnosis and Therapy of Human Tumors PCT PCT PCT/US03/20367 Expired
NCI E-286-2000-0-US-07 Histone Deacetylase Inhibitors in Diagnosis and Treatment of Thyroid Neoplasms US National Stage 10/250,320 Abandoned
NIDDK E-202-2003-0-US-01 Adenosine Derivatives As A3 Receptor Agonists US 60/482,459 Abandoned
NCI E-090-2001-0-US-04 Hexahydrofuro[2,3-B]furan-3-yl-n{3[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor US CON 10/606,342 7157495 Expired PDF
NCI E-283-2000-0-JP-06 A Chimeric Protein Comprising Non-Toxic Pseudomonas Exotoxin A And Type IV Pilin Sequences JP National Stage 2002-561503 Abandoned
NCI E-232-1998-0-US-03 Methods for Identifying Modulators of GADD45 Polypeptide Activity US DIV 10/600,158 7005419 Abandoned PDF
NINDS E-084-2003-1-US-01 Identification, Quantification, and Characterization of T Cells and T Cell Antigens US 60/480,083 Abandoned
NCI E-326-2002-1-US-01 Triplex Hairpin Ribozyme Directed Against Human Papillomavirus Type 16 (HPV-16) E6 And E7 MRNA US 60/480,815 Abandoned
NHGRI E-331-2003-0-US-01 Method For The Treatment Of Hypertension US 60/280,422 Abandoned
NIDDK E-143-2003-0-US-01 Tightly Binding Antibodies Directed Against The Internal Trimeric Coiled-coil Of GP41 Inhibit HIV-Envelope Mediated Cell Fusion US 60/480,070 Abandoned
NIDCD E-222-2003-0-US-01 Functional Variants of Human Taste Receptor Genes US 60/480,035 Abandoned
NCI E-056-2002-0-AU-06 SPECIFICITY GRAFTING OF A MURINE ANTIBODY ONTO A HUMAN FRAMEWORK AU National Stage 2003243651 Abandoned
NCI E-056-2002-0-PCT-02 SPECIFICITY GRAFTING OF A MURINE ANTIBODY ONTO A HUMAN FRAME WORK PCT PCT PCT/US03/19333 Expired
NCI E-056-2002-0-EP-05 SPECIFICITY GRAFTING OF A MURINE ANTIBODY ONTO A HUMAN FRAMEWORK EP National Stage 03760462.6 Abandoned
NCI E-056-2002-0-CA-04 SPECIFICITY GRAFTING OF A MURINE ANTIBODY ONTO A HUMAN FRAMEWORK CA National Stage 2487321 Abandoned
NCI E-175-2002-0-US-02 METHOD OF TREATING ISCHEMIA/REPERFUSION INJURY WITH NITROXYL DONORS US ORD 10/463,084 Abandoned
NINDS E-292-1999-0-US-05 LOW OXYGEN CULTURING OF CENTRAL NERVOUS SYSTEM PROGENITOR CELLS US DIV 10/462,896 Abandoned
NIAID E-093-2003-1-US-01 Recovery of Recombinant Human Metapneumovirus (HMPV) from cDNA and Use of Recombinant HMPV in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against HMPV and Other Human Pathogens US 60/478,667 Abandoned
NIAID E-083-2005-0-US-01 Negative Strand RNA Virus Replicon US 60/478,521 Abandoned
NCI E-124-1996-0-US-05 FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATING GENE 1 AND RELATED COMPOSTITIONS AND METHODS US DIV 10/461,180 6831170 Expired PDF
NCI E-279-1999-0-US-03 AMINOFLAVONE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE US National Stage 10/240,883 6812246 Abandoned PDF
NCI E-063-2003-0-US-01 Rapamycin Resistant T Cells and Therapeutic Uses Thereof US 60/478,736 Abandoned
NCI E-210-1998-0-US-05 Aspartic Protease Inhibitors US DIV 10/458,873 7132420 Abandoned PDF
NCI E-306-2000-0-PCT-02 CROSS-LINKED NITRIC OXIDE-RELEASING POLYAMINE COATED SUBSTRATES, COMPOSITIONS COMPRISING SAME AND METHODS OF MAKING SAME. PCT PCT PCT/US2003/018270 Expired